832-497-2220 [email protected]

Aesthetic Medicine

China’s aesthetic medicine industry has entered a stage of rapid development. According to Frost & Sullivan, its compound growth rate of 23.6% from 2014 to 2018. In 2018, the scale of China’s aesthetic medicine industry was RMB¥121.7 billion (approximately USD$ 17.4 billion), a year-on-year increase of 22.6%. Meanwhile, the number of medical aesthetic projects in China reached 10.2 million in 2017, surpassing Brazil to become the world’s second-largest country in medical aesthetics after the United States. With the increasing demand for women’s medical aesthetics, technology advancement, and policy improvement, the period of rapid development of the medical aesthetics industry has arrived. The market scale of China’s medical aesthetics is projected to reach RMB¥ 360.1 billion (USD$ 51.6 billion) in 2023.

Submitted Projects:

Project ID: AES101

Category: Medical Beauty

Keyword: Hair regeneration

Project/Product Summary:

Project AES101 develops the patented technology that can stimulate the body’s stem cells to regenerate tissues and restore youthful functions. Histogen’s main product application is HSXXX, which is a soluble preparation in clinical development and can be used for hair regrowth injections.

Indications: Hair growth, skin care, tissue enhancement and dermal fillers. Including orthopedic indications (such as cartilage formation and spinal disc repair) and treatment methods for wound healing.

Stage: Clinical Phase II

Partnering Objectives: Fundraising, Commercial Licensing

Country: USA

Project ID: AES102

Category: Medical Beauty

Keyword: Mediator VEGF, Ang-2, bradykinin inhibitor

Project/Product Summary:

Project AES102 is developed by Korean biopharmaceutical company focused on the discovery, development and commercialization of innovative global therapeutics for the treatment of aged-related vascular and intractable metabolic diseases and cancers. The research efforts are focused on the development of therapeutics inhibiting endothelial dysfunction by tackling multiple mediators including VEGF, Ang-2, bradykinin and so on and maintain vascular homeostasis which is one of the most essential elements in controlling diseases and aging.

Indications: Senile vascular disease and refractory metabolic disease and cancer

Stage: Pre-Clinical

Partnering Objectives: Fund raising

Country: South Korea

Project ID: AES103

Category: Medical Beauty

Keyword: Anti-Aging

Project/Product Summary:

Project AES103 has developed a proprietary next-generation AI platform for big biomedical data analysis to discover therapeutics targeting aging. Primary indication: Accelerated aging after chemotherapy/cancer supportive care. Follow-up indications: metabolic syndrome (including NAEFL/NASH); regeneration; rejuvenation; neurogenesis/neuroplasticity; other “hallmarks of aging”. Facts about the company: Top-notch AI investors with exits to Google and Facebook; outstanding lifespan extension and rejuvenation in aged mice (collaboration with B. Kennedy from NUS (ex CEO of the Buck Institute of Aging); collaborations with researchers from Harvard, MIT, Roswell Park Cancer Center.

Indications: Accelerated aging after chemotherapy/cancer support treatment, metabolic syndrome (including NAEFL/NASH)

Stage: Technology platform

Partnering Objectives: US$10 million in financing, Exit: 4 years after proven efficacy in humans

Country: Singapore

Potential Chinese Partners: